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Background: The monitoring of children with asthma in primary care is based on the occur-
rence and frequency of asthma symptoms. We questioned whether the current approach is ad-
equate to identify all children in whom a sufficient level of asthma control is not achieved.
Aim: The aim of this study is to illustrate that in some children asthma was incorrectly consid-
ered controlled, because the children failed to report current symptoms of asthma.
Patients and methods: One hundred and nineteen children were identified with recent wheez-
ing plus moderate or severe airway hyperresponsiveness. We analyzed whether these children
reported current symptoms of asthma (as normally questioned during a routine visit).
Results: In 20 children (18%) current asthma symptoms were absent despite moderately or
severe airway hyperresponsiveness and wheezing in the last year. In addition, the usage of
controller medication was very poor.onsiveness; FEV1, forced expiratory volume in 1 s; GP, general practitioner; ICS, inhalation cortico-
hacholine which gives a 20% fall in FEV1 compared to baseline.
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1154 W. Hagmolen of ten Have et al.Conclusion: We conclude that the general practitioner has insufficient tools to adequately
assess asthma control in all children. The assessment of airway hyperresponsiveness as an
additional guide to manage asthma in children in general practice is recommended. In this
way, better asthma control can be achieved.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
In asthma, disease control refers to control of the clinical
manifestations. Therefore, it is current practice to use
a symptom-based approach for the monitoring of patients
with asthma in primary care settings. However, recent
studies have shown that treatment based on symptoms
alone is inferior to treatment also based on an additional
(inflammatory) marker. Two studies demonstrated that
treatment based on airway hyperresponsiveness (AHR)
and sputum eosinophils, respectively, resulted in a decrease
of asthma exacerbations compared to treatment based on
symptoms alone.1,2 Two other studies, one in adults and
one in children, showed beneficial effects when informa-
tion about the patients exhaled nitric oxide was used in
addition to treatment based on symptoms only.3,4 AHR is
one of the hallmarks of asthma. It is an objective parame-
ter of asthma reflecting the severity of airway disease.1 In
our opinion, children with moderate or severe AHR should
be treated with controller medication if AHR is part of
the clinical manifestation of asthma. In an earlier paper
we reported on a large group of children treated for their
asthma in general practice. We showed that in most chil-
dren the severity of AHR in these children could not be
suspected by their general practitioner (GP), based on
symptoms alone.5 In the present study, children with bor-
derline to severe AHR were followed for one year to study
prospectively the relationship between symptoms and
AHR. In addition to the previous report we also questioned
parents whether children had symptoms of wheezing during
the study year. We hypothesized that in a substantial num-
ber of asthmatic children presenting with less pronounced,
atypical or trivialised symptoms of asthma, the severity of
their disease could be easily underestimated.
Methods
Patients
All children described in this paper participated in an
intervention study that compared different methods to
improve disease control in childhood asthma in general
practice. GPs were subject to one to three cumulative
strategies to improve control in childhood asthma: (1)
distribution of an asthma guideline, (2) a single educational
session and (3), a onetime individualized treatment advice
based on symptoms and lung function including the degree
of AHR. Children were eligible to participate in the original
study if at least two prescriptions of b2-mimetics and/or an
inhaled corticosteroid (ICS) were prescribed in the year
before invitation. The flow sheet of participation selection
is shown in Fig. 1. The patient selection is described in
more detail elsewhere.5,6Study design and patient selection
At the end of the original one-year study, 362 asthmatic
children were re-evaluated on asthma symptoms, Peak
Expiratory Flow (PEF) variability, degree of AHR, and
medication usage. Parents were asked to fill in a standard
questionnaire on asthma symptoms of their child in the past
year. AHR was assessed by means of a methacholine in-
halation challenge test when the FEV1 was 75% of pre-
dicted. The method used is validated in children and
described elsewhere.7 The degree of AHR was expressed
as a PD20, a provocation dose that induces a 20% fall in
FEV1 from baseline. Severe AHR was defined as a PD20 below
75 mg methacholine, moderately severe AHR as a PD20 be-
low 300 mg, mild AHR as a PD20 below 1000 mg and border-
line to normal AHR as a PD20 above 1000 mg according to
the classification used by Sont and colleagues.1 Children
were challenged to a maximal cumulative dose of 3600 mg
methacholine. Children with a baseline FEV1 value below
75% of predicted were not challenged. These children
were classified as having severe AHR.
We analyzed whether children scored current symp-
toms of asthma in their diary. The diary was filled in
during two weeks prior to the inhalation challenge test. In
the diary the frequency of asthma related symptoms,
cough, wheeze and shortness of breath was scored (‘0’ (no
complaints), ‘1’ (once a day), ‘2’ (more than once a day),
and ‘3’ (whole day)). Total day as well as total night
scores could range from 0 to 9. Moreover, we calculated:
(1) a total symptom score and (2) a symptom-free days
score, defined as the total number of symptom-free days
(range 0e14).
PEF variability was also assessed in the two-week diary.
Children were provided with a ‘Personal Best’ peak flow
meter. The best of three PEF measurements was used and
the percentage of predicted was calculated.8,9 PEF variabil-
ity was calculated as: evening PEF value minus the morning
PEF value divided by their mean value.
The number of prescribed inhalers for ICS and b2-
adrenergic drugs was obtained from electronic medication
lists of the GPs.
Statistical analysis
Data analysis was performed with the statistical package
SPSS (version 12.2) (SPSS, Inc., Chicago, IL). To compare
groups with regard to continuous normally distributed data,
independent samples t-tests were performed.
Results
Of 404 children who were included on the basis of AHR at
the start of the study, 362 participants (90%) completed
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Figure 1 Design of the intervention study and flow diagram of participants in accordance with CONSORT (Consolidated Standards
of Reporting Trials). HCC Health Care Centre.
Assessment of the level of asthma control 1155follow-up for one year. From these children we got 328
completed diaries (91%), characteristics of these children
are shown in Table 1. At evaluation at the end of the in-
tervention study, 167 children (51%) had moderate or se-
vere AHR (Table 1). Parents of 119 of these children
(71%) reported wheezing in the last 12 months (‘recent
wheezing’). Fig. 2 shows the percentages of children
with recent wheezing in subgroups of children with re-
spect to lung function and degree of AHR. In contrast to
the report of ‘recent wheezing’, 20 children (17%) with
moderate to severe AHR did not report wheezing, cough
or shortness of breath in the last two weeks, despite the
fact that nine of these children showed severe AHR
(PD20< 75 mg). The PEF variability of these 20 childrenwas significantly lower as compared to the children who
reported symptoms in their diary (4.6% versus 7.8%,
p< 0.01). Consistently with their lack of symptoms, these
20 children were prescribed fewer b2 agonists (Table 1).
The mean usage of inhaled corticosteroids was poor in
both groups.
Children with moderate or severe AHR without ‘recent
wheezing’ report less symptoms of asthma in their diary
than those with ‘recent wheezing’ (median 0.1 versus 1.1;
pZ 0.005). Subsequently, they were prescribed less short
acting reliever medication (median 16 versus 55 mg/day;
pZ 0.04). Except for these differences in symptoms and
usage of reliever medication, no significant differences
with respect to lung function were found.
Table 1 Characteristics of 328 children with asthma stratified to severity of airway hyperresponsiveness (AHR) and recent
wheezing
Moderate or severe AHR Mild AHR
or borderline
to normalc
AbsentaPresent
Symptoms last 14 days
Missing
data
Wheezing last year non-wheezingb
participants (n=328)
Number 92 20 7 48 161
Age 12.0 (2.6) 12.6 (2.5) 11.6 (1.3) 10.8 (2.4) 10.6 (2.5)
Gender, male 47 (51) 8 (40) 5 (71) 29 (60) 103 (58)
Symptom-free days 5.0 (0e13) 14** e 13* (0e14) 12** (0e14)
Symptom score 1.4 (0e9) 0** e 0.1* (0e5) 0.2* (0e8)
FEV1, % predicted 93 (56e125) 93 (76e114) 91.0 (71e103) 96 (76e118) 100** (78e168)
PEF variability 7.8 (2e27) 4.6** (2e11) e 6.8 (1.3e20.1) 5.3** (0.9e24.7)
Severe AHR (%) 44 (48) 9 (45) 2 (29) 16 (33) e
ICS, mg/day 30 (0e410) 20 (0e140) 30 (0e150) 20 (0e200) 30 (0e300)
b2- mimetic, mg/day 70 (0e660) 50* (0e230) 30 (0e60) 20* (0e590) 20** (0e400)
Data are presented as mean with SD, as number of children with percentage of subgroup, or as median with range.
*p< 0.05, and **p< 0.01.
a Statistical comparison versus children with moderately or severe AHR and wheezing and present symptoms.
b Statistical comparison versus children with moderately or severe AHR and wheezing.
c Statistical comparison versus children with moderately or severe AHR.
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Figure 2 The percentage of 362 children who had wheezing
in the last 12 months (as reported by the parents) is shown per
subgroup. Children were stratified according to the degree of
airway hyperresponsiveness (AHR).
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significantly less asthma symptoms, had more symptom-
free days, had better lung function (PEF variability and
FEV1) and were prescribed less short acting reliever medi-
cation compared to children with moderate or severe AHR
(Table 1). There was no difference in mean prescribed con-
troller medication (ICS).
Discussion
In this study we showed that almost one-sixth of asthmatic
children with ‘recent wheezing’ and moderate or severe
AHR, were not identified as ‘at risk’ when questioning
current asthma symptoms only. These children could be
easily missed as ‘not well controlled’ by the GP at a routine
visit. Eight of these children were not prescribed any
controller medication in the previous year; the majority
of the others (except four), probably did not use their
medication regularly. These findings support our earlier
conclusion that it is difficult if not impossible to assess the
severity of asthma in a number of ‘‘at risk’’ children by
means of only questioning asthma symptoms. Also lung
function (PEF variability and FEV1) is often not very helpful
because of relative minor abnormalities.
All children in this study were treated for their asthma in
general practice. A priori, participants of our study were
likely to have (a diagnosis of) asthma because they were
selected on the basis of prescribed asthma medication,
which they were prescribed in the year prior to the start of
the original study. Furthermore, all children were included
Assessment of the level of asthma control 1157for follow-up because of the presence of AHR. AHR could
be mild or even borderline normal, but in 212 children out of
362 (59%), AHR was moderate or severe at inclusion in the
study.6
Furthermore, our data suggest that it is relevant to
question wheezing during the last year. Of all children with
severe AHR, 65% were identified on the basis of the
prevalence of recent wheezing and all children with an
FEV1 below 75% of predicted were selected. However, ques-
tioning wheezing is not very specific to assess the severity
of asthma.
The severity of AHR reflects the severity of asthma,1 it is
a tool to monitor asthma treatment10 and it predicts the
outcome of asthma.11 Furthermore, it is an objective char-
acteristic of asthma. AHR is considered to be one of the
major consequences of airway inflammation and remodel-
ing. The degree of AHR has been shown to correlate both
with an increase in airway inflammatory cells and with al-
tered structural components in the airway wall, such as
a deposition of subepithelial collagen or proteoglycans.12,13
The frequently observed lack of association between AHR
and airway inflammation supports the assertion that other
factors such as remodeling may be involved.14 Airway hy-
perresponsiveness is a key feature in asthma, but also oc-
curs during other conditions, such as active smoking,
respiratory infections, specific allergens and vigorous exer-
cise.15 We hypothesize that this group of children (occa-
sional presentation with symptoms at the GP and
moderate to severe AHR) is under treated. However, we
are not aware of intervention studies with ICS in this
specific group, and can only guess what the benefits of
such treatment would be.
There are several possible explanations for the appar-
ent absence of symptoms in children. It maybe that
children trivialize their asthma, or that children and
parents do not recognize asthma symptoms as relevant
enough to report. Because the perception of symptoms
associated with airway obstruction follows a normal unim-
odal distribution in patients with asthma, patients with
marked reductions in expiratory flow can sometimes be
asymptomatic or have minimal symptoms.16 Perceptual
accuracy may be affected by physiological, psychological,
cognitive and parentechild factors.17 The absence of
symptoms may be due to insufficient triggers, such as
lack of exercise or absence of exposure to relevant aller-
gens or respiratory irritants. Or it simply may be the
natural course of the disease, which is known for its inter-
mittent character. This is demonstrated in two studies who
found large variations in morning PEF, asthma symptoms,
and use of rescue medication, with the result that individ-
ual patients moved frequently across different severity
categories over time.18,19
In conclusion, a group of children with asthma in general
practice is difficult to manage because reporting of current
asthma related symptoms is absent. The children described
in this study were found to have moderate or severe AHR.
The assessment of AHR in these children is considered to be
an additional and necessary tool to estimate the severity
and control of the disease. Based on current guidelines
these children would be incorrectly considered well con-
trolled. At present, no consensus exists on how to monitor
these children. We recommend monitoring of AHR or othervalidated inflammatory markers in children who have had
airway symptoms in the past year but do not report current
asthma related complaints. They might be poorly con-
trolled and in need of controller medication.
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